Open Targets

Open Targets is a partnership between academia and industry to transform drug discovery through the identification and prioritisation of drug targets.

There are two components within Open Targets knowledge cycle: data integration and data generation.

We integrate large-scale genetics and genomics data in easy-to-use bioinformatics interface such as Open Targets Platform and Open Targets Genetics. We generates new data using human cellular models (e.g. organoids, iPSCs) and genome editing (CRISPR/Cas9 screens) to identify new therapeutic targets in Oncology, Immunology and Neurodegeneration.

We bring together expertise from academic institutes and pharmaceutical companies to systematically identify and prioritise targets from which safe and effective medicines can be developed.

Follow us on Twitter, LinkedIn or post on the Open Targets Community (community.opentargets.org) with your questions or suggestions.